LAPIX Therapeutics adds biotech dealmaking expertise as LPX-TI641 studies progress
LAPIX adds Nimbus CEO Abbas Kazimi to its board as LPX-TI641 advances in Phase 1b autoimmune trials and prepares for Phase 2 decisions.
Pharma & Biotech
Pharma & Biotech
Nimbus Therapeutics tests a dual inflammation and repair thesis with SIK2 inhibitors
Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.